Paratek Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Paratek Pharmaceuticals, Inc.‘s stocks are currently a part of 35 hedge funds’ portfolios, which represents 51.39% of the total amount of its stocks outstanding. This makes up a total of 27.94M shares of Paratek Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -30.62% or -12.33M shares fewer. As for the holding position changes, 31.43% (11) of current hedge fund investors increased the number of shares held, 31.43% (11) of current holders sold a part of the shares held, and 34.29% (12) closed the holdings completely. 3 hedge funds are new holders of Paratek Pharmaceuticals, Inc. stock in Q1 2023, it is 8.57% of total holders.
Hedge funds holding Paratek Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 111 |
|---|---|
| Q3 2018 | 105 |
| Q4 2018 | 102 |
| Q1 2019 | 92 |
| Q2 2019 | 86 |
| Q3 2019 | 90 |
| Q4 2019 | 90 |
| Q1 2020 | 82 |
| Q2 2020 | 96 |
| Q3 2020 | 99 |
| Q4 2020 | 108 |
| Q1 2021 | 107 |
| Q2 2021 | 117 |
| Q3 2021 | 102 |
| Q4 2021 | 100 |
| Q1 2022 | 97 |
| Q2 2022 | 82 |
| Q3 2022 | 71 |
| Q4 2022 | 77 |
| Q1 2023 | 35 |
Hedge funds changes in Paratek Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 13 | 46 | 30 | 16 | 6 |
|---|---|---|---|---|---|
| Q3 2018 | 13 | 39 | 28 | 19 | 6 |
| Q4 2018 | 21 | 31 | 33 | 23 | -6 |
| Q1 2019 | 7 | 33 | 29 | 17 | 6 |
| Q2 2019 | 13 | 23 | 29 | 16 | 5 |
| Q3 2019 | 16 | 32 | 21 | 11 | 10 |
| Q4 2019 | 14 | 38 | 23 | 13 | 2 |
| Q1 2020 | 9 | 27 | 32 | 14 | 0 |
| Q2 2020 | 23 | 36 | 25 | 11 | 1 |
| Q3 2020 | 18 | 34 | 29 | 14 | 4 |
| Q4 2020 | 26 | 34 | 30 | 16 | 2 |
| Q1 2021 | 9 | 24 | 41 | 10 | 23 |
| Q2 2021 | 25 | 36 | 34 | 15 | 7 |
| Q3 2021 | 9 | 38 | 34 | 22 | -1 |
| Q4 2021 | 10 | 36 | 37 | 11 | 6 |
| Q1 2022 | 12 | 37 | 31 | 14 | 3 |
| Q2 2022 | 12 | 22 | 31 | 25 | -8 |
| Q3 2022 | 5 | 24 | 19 | 16 | 7 |
| Q4 2022 | 14 | 19 | 31 | 8 | 5 |
| Q1 2023 | 3 | 11 | 11 | 12 | -2 |
Hedge funds changes in Paratek Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 2,312,000 | 2,897,000 |
|---|---|---|
| Q3 2018 | 290,000 | 874,000 |
| Q4 2018 | 798,000 | 550,000 |
| Q1 2019 | 720,000 | 164,000 |
| Q2 2019 | 49,000 | 0 |
| Q3 2019 | 514,000 | 269,000 |
| Q4 2019 | 350,000 | 414,000 |
| Q1 2020 | 580,000 | 482,000 |
| Q2 2020 | 1,476,000 | 708,000 |
| Q3 2020 | 2,211,000 | 399,000 |
| Q4 2020 | 2,110,000 | 1,212,000 |
| Q1 2021 | 776,000 | 1,466,000 |
| Q2 2021 | 760,000 | 2,368,000 |
| Q3 2021 | 601,000 | 1,414,000 |
| Q4 2021 | 424,000 | 382,000 |
| Q1 2022 | 25,000 | 160,000 |
| Q2 2022 | 173,000 | 99,000 |
| Q3 2022 | 411,000 | 159,000 |
| Q4 2022 | 107,538 | 17,399 |
| Q1 2023 | 31,844,000 | 8,384,000 |